UBS analyst Danielle Antalffy reiterated a Buy rating on Boston Scientific today and set a price target of $140.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Danielle Antalffy has given her Buy rating due to a combination of factors that highlight Boston Scientific’s strong growth trajectory and robust product portfolio. The company has demonstrated sustained momentum in its organic sales and earnings per share (EPS) growth, outperforming both UBS’s and market consensus estimates. This growth is driven by key products like FARAPULSE and WATCHMAN, which have shown significant sales acceleration, indicating a strong market position despite increasing competition.
Moreover, Antalffy notes that Boston Scientific’s valuation is attractive, with shares trading below their 52-week highs, providing room for further upside. The company’s updated guidance for 2025 reflects increased confidence in its innovative product offerings, with sales and EPS estimates revised upwards. This positive outlook, coupled with a strategic price target increase to $140, underpins the Buy recommendation, suggesting that Boston Scientific is well-positioned for continued success in the MedTech sector.
Antalffy covers the Healthcare sector, focusing on stocks such as Boston Scientific, Abbott Laboratories, and Dexcom. According to TipRanks, Antalffy has an average return of 2.8% and a 52.08% success rate on recommended stocks.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $118.00 price target.